1 terminated. 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Terminated 1 |
Follow KD019: new trials by email Literature Review of KD019 trials Research Report on KD019
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| KD019 Versus Erlotinib in Subjects With Stage IIIB/IV Non Small Cell Lung Cancer With Progression After First- or Second-Line Chemotherapy KD019, Erlotinib - Carcinoma, Non-Small-Cell Lung | Phase 3 | Terminated | Kadmon Corporation, LLC | 8 | 2011-12-14 | 2022-05-13 |
Carcinoma, Non-Small-Cell Lung (1)
United States (1)